About this trial
This study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing. Gene expression profiles, mutational profiles, and transcript isoform-level data will be analyzed in the context of patient information, clinicopathological variables, and outcome, with the purpose to develop new molecular diagnostic assays for breast cancer. Additional genome-scale RNA, DNA, and protein analyses will be performed in the future.
Eligibility criteria
Qualifiers
suspicion or confirmed diagnosis of primary breast cancer
signed informed consent
Disqualifiers
lack of signed informed consent
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Lund University
Lead sponsor
South Sweden Breast Cancer Group
Collaborator
Mrs. Berta Kamprad Foundation
Collaborator
U-CAN
Collaborator